SV2017005368A - [1,2,4] triazolo [4,3-b] piridazinas para su uso en el tratamiento de enfermedades proliferativas - Google Patents

[1,2,4] triazolo [4,3-b] piridazinas para su uso en el tratamiento de enfermedades proliferativas

Info

Publication number
SV2017005368A
SV2017005368A SV2017005368A SV2017005368A SV2017005368A SV 2017005368 A SV2017005368 A SV 2017005368A SV 2017005368 A SV2017005368 A SV 2017005368A SV 2017005368 A SV2017005368 A SV 2017005368A SV 2017005368 A SV2017005368 A SV 2017005368A
Authority
SV
El Salvador
Prior art keywords
piridazines
triazolo
treatment
proliferative diseases
formula
Prior art date
Application number
SV2017005368A
Other languages
English (en)
Spanish (es)
Inventor
Robert Hugh Bradbury
Alfred Arthur Rabow
Michael James Waring
James Francis Mccabe
Steven Christopher Glossop
Arshed Mahmood
Zoe Ann Cotter
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SV2017005368A publication Critical patent/SV2017005368A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • E—FIXED CONSTRUCTIONS
    • E21—EARTH OR ROCK DRILLING; MINING
    • E21B—EARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B7/00—Special methods or apparatus for drilling
    • E21B7/04—Directional drilling
    • E21B7/06—Deflecting the direction of boreholes
    • E—FIXED CONSTRUCTIONS
    • E21—EARTH OR ROCK DRILLING; MINING
    • E21B—EARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B7/00—Special methods or apparatus for drilling
    • E21B7/04—Directional drilling
    • E21B7/06—Deflecting the direction of boreholes
    • E21B7/062—Deflecting the direction of boreholes the tool shaft rotating inside a non-rotating guide travelling with the shaft
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mining & Mineral Resources (AREA)
  • Geology (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Geochemistry & Mineralogy (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Fluid Mechanics (AREA)
  • Environmental & Geological Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SV2017005368A 2014-07-28 2017-01-27 [1,2,4] triazolo [4,3-b] piridazinas para su uso en el tratamiento de enfermedades proliferativas SV2017005368A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462029676P 2014-07-28 2014-07-28
PCT/GB2015/052143 WO2016016618A1 (en) 2014-07-28 2015-07-24 [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
SV2017005368A true SV2017005368A (es) 2017-05-12

Family

ID=53761420

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2017005368A SV2017005368A (es) 2014-07-28 2017-01-27 [1,2,4] triazolo [4,3-b] piridazinas para su uso en el tratamiento de enfermedades proliferativas

Country Status (37)

Country Link
US (5) US9944650B2 (OSRAM)
EP (1) EP3174881B1 (OSRAM)
JP (1) JP6592503B2 (OSRAM)
KR (1) KR20170033427A (OSRAM)
CN (1) CN106536524B (OSRAM)
AP (1) AP2017009700A0 (OSRAM)
AU (1) AU2015295120B2 (OSRAM)
BR (1) BR112017001160A2 (OSRAM)
CA (2) CA3185741A1 (OSRAM)
CL (1) CL2017000223A1 (OSRAM)
CO (1) CO2017001918A2 (OSRAM)
CY (1) CY1120602T1 (OSRAM)
DK (1) DK3174881T3 (OSRAM)
DO (1) DOP2017000018A (OSRAM)
EA (1) EA032654B9 (OSRAM)
ES (1) ES2670444T3 (OSRAM)
GT (1) GT201700016A (OSRAM)
HR (1) HRP20180788T1 (OSRAM)
HU (1) HUE037571T2 (OSRAM)
IL (1) IL250104B (OSRAM)
LT (1) LT3174881T (OSRAM)
MX (1) MX374539B (OSRAM)
MY (1) MY187251A (OSRAM)
NI (1) NI201700006A (OSRAM)
NO (2) NO2719005T3 (OSRAM)
PE (1) PE20170527A1 (OSRAM)
PH (1) PH12017500159B1 (OSRAM)
PL (1) PL3174881T3 (OSRAM)
PT (1) PT3174881T (OSRAM)
RS (1) RS57242B1 (OSRAM)
SG (1) SG11201700419SA (OSRAM)
SI (1) SI3174881T1 (OSRAM)
SM (1) SMT201800260T1 (OSRAM)
SV (1) SV2017005368A (OSRAM)
TN (1) TN2017000018A1 (OSRAM)
WO (1) WO2016016618A1 (OSRAM)
ZA (1) ZA201701207B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2719005T3 (OSRAM) * 2014-07-28 2018-01-20
CN110317216A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑并哒嗪类衍生物在医药领域的应用
TWI816880B (zh) * 2018-09-13 2023-10-01 大陸商恒翼生物醫藥（上海）股份有限公司 治療前列腺癌之組合療法
BR112022007210A2 (pt) 2019-10-14 2022-07-05 Astrazeneca Ab Terapia de combinação para tratar malignidade hematológica
IL294399A (en) 2020-01-09 2022-08-01 Astrazeneca Ab Combination therapy for treating cancer
CN113143930B (zh) * 2021-04-08 2023-05-30 深圳湾实验室 化合物在制备SARS-Cov-2 E蛋白抑制剂中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525065D0 (en) * 2005-12-08 2006-01-18 Novartis Ag Organic compounds
RU2008127263A (ru) 2005-12-08 2010-01-20 Новартис АГ (CH) ПИРАЗОЛ [1,5-a] ПИРИДИН-3-КАРБОНОВЫЕ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ EphB-И VEGFR2-КИНАЗЫ
CN101952286A (zh) 2007-12-21 2011-01-19 阿斯利康(瑞典)有限公司 用于治疗和雄激素受体有关的病症的双环衍生物
AU2010212590B2 (en) * 2009-02-10 2013-01-10 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
MX2011012055A (es) * 2009-05-11 2011-12-06 Astrazeneca Ab [1,2,4] triazolo [4,3-b] piridazinas como ligandos del receptor de androgeno.
RS53179B (sr) 2009-11-05 2014-06-30 Glaxosmithkline Llc Benzodiazepinski inhibitor bromodomena
US9328117B2 (en) * 2011-06-17 2016-05-03 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9422290B2 (en) * 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
NO2719005T3 (OSRAM) * 2014-07-28 2018-01-20

Also Published As

Publication number Publication date
EP3174881B1 (en) 2018-03-28
TN2017000018A1 (en) 2018-07-04
US20230035133A1 (en) 2023-02-02
NO2719005T3 (OSRAM) 2018-01-20
NI201700006A (es) 2017-08-25
AU2015295120A1 (en) 2017-02-02
US20210107905A1 (en) 2021-04-15
AU2015295120A8 (en) 2017-02-09
MX2017001218A (es) 2017-05-01
PE20170527A1 (es) 2017-05-24
MY187251A (en) 2021-09-15
DOP2017000018A (es) 2017-03-15
BR112017001160A2 (pt) 2017-11-14
KR20170033427A (ko) 2017-03-24
EP3174881A1 (en) 2017-06-07
PL3174881T3 (pl) 2018-08-31
US20170210747A1 (en) 2017-07-27
CY1120602T1 (el) 2019-12-11
US10407432B2 (en) 2019-09-10
CO2017001918A2 (es) 2017-05-10
JP6592503B2 (ja) 2019-10-16
CA3185741A1 (en) 2016-02-04
CA2956421A1 (en) 2016-02-04
CL2017000223A1 (es) 2017-08-25
US11407755B2 (en) 2022-08-09
EA201790179A1 (ru) 2017-07-31
IL250104B (en) 2018-10-31
RS57242B1 (sr) 2018-07-31
US10766905B2 (en) 2020-09-08
IL250104A0 (en) 2017-03-30
NO3174881T3 (OSRAM) 2018-08-25
PT3174881T (pt) 2018-05-25
HRP20180788T1 (hr) 2018-06-29
AU2015295120B2 (en) 2018-02-01
MX374539B (es) 2025-03-06
LT3174881T (lt) 2018-06-11
ZA201701207B (en) 2018-12-19
US20200055861A1 (en) 2020-02-20
EA032654B9 (ru) 2019-07-31
CN106536524A (zh) 2017-03-22
SG11201700419SA (en) 2017-02-27
SMT201800260T1 (it) 2018-07-17
CN106536524B (zh) 2019-11-15
DK3174881T3 (en) 2018-06-06
HUE037571T2 (hu) 2018-09-28
US20180230158A1 (en) 2018-08-16
PH12017500159A1 (en) 2017-07-10
GT201700016A (es) 2018-12-19
ES2670444T3 (es) 2018-05-30
AP2017009700A0 (en) 2017-01-31
CA2956421C (en) 2023-03-14
WO2016016618A1 (en) 2016-02-04
PH12017500159B1 (en) 2020-12-09
EA032654B1 (ru) 2019-06-28
US9944650B2 (en) 2018-04-17
SI3174881T1 (en) 2018-06-29
JP2017522338A (ja) 2017-08-10

Similar Documents

Publication Publication Date Title
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
ECSP19024046A (es) Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje
NI201500167A (es) Compuestos químicos
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
DOP2015000170A (es) Compuestos químicos
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
GT201400196A (es) Compuestos de heterociclilo
CR20150610A (es) Compuestos de pirimidino sustituido y derivados para combatir plagas de animales
SV2017005368A (es) [1,2,4] triazolo [4,3-b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
BR112015019508A8 (pt) formas sólidas de um inibidor de cdk4/6 seletivo
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
GT201500094A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
ECSP18056196A (es) Derivados de indano
NI201500172A (es) Composiciones farmacéuticas